Bronchopneumonia

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

Retrieved on: 
Wednesday, July 20, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRSA, Patient, Streptococcus agalactiae, MSSA, Streptococcus anginosus group, Bacteria, Food and Drug Administration, Tablet, Culture, Drug of last resort, Marketing, Pyelonephritis, ABSSSI, Review, Staphylococcus aureus, Infection, Streptococcus constellatus, Diarrhea, U.S. Securities and Exchange Commission, Human, Union, Research, Enterococcus, Merck, Moxifloxacin, Streptococcus intermedius, Private Securities Litigation Reform Act, Urinary tract infection, GLOBE, Streptococcus anginosus, Food, COVID-19, Conference, Nausea, Streptococcus pyogenes, Vomiting, Cutis laxa, Linezolid, Fosfomycin, Enterococcus faecalis, Bronchopneumonia, Complicated, Therapy, NASDAQ, Gram, Cystic fibrosis, Pharmaceutical industry, Streptococcus

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

Retrieved on: 
Monday, July 18, 2022
Nausea, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intermediary, Bacteria, Bacterial pneumonia, Cutis marmorata telangiectatica congenita, Diarrhea, GLOBE, Food, Urinary tract infection, Fosfomycin, Infection, Moxifloxacin, Marketing, Human, Linezolid, Pyelonephritis, NASDAQ, Tablet, Vomiting, COVID-19, Bronchopneumonia, Food and Drug Administration, Therapy, Merck, NPU, Pharmaceutical industry

Nabriva will be the exclusive supplier of XENLETA to Er-Kim.

Key Points: 
  • Nabriva will be the exclusive supplier of XENLETA to Er-Kim.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.

Community-Acquired Bacterial Pneumonia (CABP) Market and Epidemiology Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 11, 2022
Health, Pharmaceutical, News, Disease, Epidemiology, United Kingdom, Therapy, Acquisition, Awareness, Research, Clinical trial, Bronchopneumonia, Vaccine, Pharmaceutical industry

The "Community-Acquired Bacterial Pneumonia (CABP) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Community-Acquired Bacterial Pneumonia (CABP) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • Drug chapter segment of the Community-Acquired Bacterial Pneumonia (CABP) report encloses the detailed analysis of Community-Acquired Bacterial Pneumonia (CABP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
  • The analysis covers Community-Acquired Bacterial Pneumonia (CABP) market uptake by drugs; patient uptake by therapies; and sales of each drug.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Community-Acquired Bacterial Pneumonia (CABP) emerging therapies.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, July 1, 2022
LinkedIn, Degenerative disease, GLOBE, Anthrax, Company, Public health, Employment, Development, Acne, Biomedical Advanced Research and Development Authority, Bronchopneumonia, LLC, U.S. Department of Defense Strategy for Operating in Cyberspace, Nasdaq, Office of Inspector General, U.S. Department of Health and Human Services, BARDA, NASDAQ, ABSSSI, Government, Twitter, NTM, Pharmaceutical industry, Vaccine

Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Key Points: 
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)

Retrieved on: 
Tuesday, June 21, 2022
Biomedical Advanced Research and Development Authority, Review, Fever, FDA, Fatigue, Cough, Public health, Tetracycline, Risk, Degenerative disease, Safety, Annual report, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Government, BARDA, IV, Security (finance), U.S. Securities and Exchange Commission, Anthrax, LLC, MAB, Mycobacterium abscessus, ABSSSI, LinkedIn, Fast Track, Disease, Mycobacterium avium complex, Bacteria, Nasdaq, Development, Gram, Twitter, MAC, Food, Patient, Bronchopneumonia, Acne, Urinary tract infection, Office of Inspector General, U.S. Department of Health and Human Services, NTM, GLOBE, Pharmaceutical industry, Vaccine, Public relations

BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced the U.S. Food and Drug Administration has granted Fast Track designation for the oral and IV formulations of the company’s novel, broad-spectrum antibiotic NUZYRA® (omadacycline) for the treatment of pulmonary Nontuberculous Mycobacterial (NTM) disease caused by both Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB). These NTM indications are rare diseases for which new therapies are desperately needed. FDA granted NUZYRA orphan drug designation for these infections in August 2021.

Key Points: 
  • FDA granted NUZYRA orphan drug designation for these infections in August 2021.
  • In the United States alone, currently NTM pulmonary infections caused by MAB affect approximately 11,500 patients while an estimated 100,000 cases are caused by MAC.
  • Treatment can often be life-long in duration and complicated by long-term tolerability challenges and multiple adverse events.
  • As noted above, Paratek is conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease caused by MAB.

Nosocomial Pneumonia Market Analysis, Insights, Epidemiology and Market Forecasts, 2019-2022 & 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Health, Other Health, SME, Report, Diagnosis, Therapy, Bronchopneumonia, Hospital-acquired infection, News, Comprehension, Lists of people executed in the United States, Epidemiology, Acquisition, Technology, Vaccine, Pharmaceutical industry

The "Nosocomial Pneumonia - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nosocomial Pneumonia - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • The Nosocomial Pneumonia market report provides current treatment practices, emerging drugs, Nosocomial Pneumonia market share of the individual therapies, current and forecasted Nosocomial Pneumonia market Size from 2019 to 2032 segmented by seven major markets.
  • The Nosocomial Pneumonia market report gives a thorough understanding of the Nosocomial Pneumonia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
  • The Nosocomial Pneumonia epidemiology division provide insights about historical and current Nosocomial Pneumonia patient pool and forecasted trend for every seven major countries.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, June 1, 2022
Company, Office of Inspector General, U.S. Department of Health and Human Services, LLC, Bronchopneumonia, Biomedical Advanced Research and Development Authority, LinkedIn, Degenerative disease, Government, Acne, U.S. Department of Defense Strategy for Operating in Cyberspace, Nasdaq, ABSSSI, Development, GLOBE, Employment, BARDA, NTM, NASDAQ, Twitter, Public health, Anthrax, Pharmaceutical industry, Vaccine

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference

Retrieved on: 
Wednesday, June 1, 2022
Office of Inspector General, U.S. Department of Health and Human Services, Conference, LLC, Bronchopneumonia, Biomedical Advanced Research and Development Authority, LinkedIn, Degenerative disease, Annual report, Security (finance), Government, Investor, U.S. Securities and Exchange Commission, Acne, U.S. Department of Defense Strategy for Operating in Cyberspace, Nasdaq, ABSSSI, Risk, Development, GLOBE, BARDA, NTM, Twitter, Public health, Anthrax, Pharmaceutical industry, Vaccine

Members of Parateks senior management team also will be available for one-on-one investor meetings June 9.

Key Points: 
  • Members of Parateks senior management team also will be available for one-on-one investor meetings June 9.
  • Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex.

Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Monday, May 16, 2022
Biomedical Advanced Research and Development Authority, Public health, U.S. Securities and Exchange Commission, Nasdaq, Government, Bronchopneumonia, Degenerative disease, Investor, NTM, U.S. Department of Defense Strategy for Operating in Cyberspace, Conference, Acne, Risk, Office of Inspector General, U.S. Department of Health and Human Services, Anthrax, LinkedIn, Twitter, LLC, Development, ABSSSI, Security (finance), Annual report, BARDA, GLOBE, Pharmaceutical industry, Vaccine

The conference will be held in-person and virtually from May 23-26, 2022, with in-person participation held at the Fontainebleau Miami Beach Hotel in Miami Beach, Florida.

Key Points: 
  • The conference will be held in-person and virtually from May 23-26, 2022, with in-person participation held at the Fontainebleau Miami Beach Hotel in Miami Beach, Florida.
  • Members of Parateks senior management team will also be available for virtual one-on-one meetings throughout the conference.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex.

Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Friday, May 13, 2022
Company, Urinary tract infection, Food, Infection, Webcast, Tuberculosis verrucosa cutis, NASDAQ, Bronchopneumonia, Therapy, Merck, Food and Drug Administration, Conference, Pyelonephritis, Tablet, Fosfomycin, GLOBE, Pharmaceutical industry

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference.

Key Points: 
  • DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.